AMU, AP-HM, CIML, INNATE PHARMA
Marseille Immunopole is born from the will of all partners to do even better and progress faster, and thus allow patients always to keep one step ahead of the disease.
At the end of 2013, Science Magazine designated immunotherapy as the major medical breakthrough of the year. Since then, the success of this new anti-cancer weapon has not been contradicted and tomorrow patients with inflammatory diseases should, in turn, benefit from this approach.
Today, our city is at the forefront of this revolution. Together, Marseille researchers, physicians and industry leaders have contributed and still contribute to the discovery, development and clinical evaluation of immunotherapy antibodies. They also develop diagnostic tools that should allow customisation of these drugs and an approach that many consider the next frontier of immunotherapy: cell therapies.
With my colleagues, I have already participated in the first part of this adventure: CIML contributed to NK immunotherapy developed by Innate Pharma, I myself cofounded the company in 1999 and created a laboratory at the Conception Hospital dedicated to the exploration of these lymphocytes. Lastly, with other immunology teachers of Aix-Marseille University, we also provide research, clinics and industry with new talents.
Marseille Immunopole is born from the will of all partners to do even better and progress faster, and thus allow patients always to keep one step ahead of the disease.#industry
Each year, a large number of clinical trials are conducted by APHM clinicians alone or in partnership with industry players in biopharmaceuticals.
AMU, AP-HM, CIML
Together, we pursue a simple goal: to better understand the alterations of energetic metabolism in pancreatic cancer cells
AMU, IPC, CRCM
Education is also one of the strategic components of the Marseille Immunopole project
AMU, AP-HM, VRCM
By creating this super innovation centre "outside the walls", which is Marseille Immunopole, we leverage our capabilities to ensure better and faster innovation.